Genfit SA (GNFT)
GNFT · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Liver / Metabolicsrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 1, 1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Pre-Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long-Term Albumin in Patients With Cirrhosis and Ascites. — United European Gastroenterol J (2026) PMID 42435328
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. — Nat Med (2026) PMID 42252333
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Genfit SA.
Full GNFT Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.